Vericel Corporation (VCEL)
Automate Your Wheel Strategy on VCEL
With Tiblio's Option Bot, you can configure your own wheel strategy including VCEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VCEL
- Rev/Share 4.7799
- Book/Share 5.921
- PB 6.7759
- Debt/Equity 0.3349
- CurrentRatio 5.0101
- ROIC -0.0068
- MktCap 2019761160.0
- FreeCF/Share 0.8732
- PFCF 46.3471
- PE 672.3266
- Debt/Assets 0.2331
- DivYield 0
- ROE 0.0109
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
Read More
Vericel Corporation: Moving From Sell To Neutral
Published: June 12, 2025 by: Seeking Alpha
Sentiment: Positive
Vericel's valuation has moderated after a 20% share price drop, prompting a shift from sell to neutral. MACI remains the company's primary growth engine, with strong sales momentum and successful surgeon training on new indications. The stock enjoys bullish analyst firm support and Vericel's balance sheet is in a strong position.
Read More
Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Vericel Corporation. (NASDAQ:VCEL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - CEO Joe Mara - CFO Conference Call Participants Ryan Zimmerman - BTIG Richard Newitter - Truist Securities Josh Jennings - TD Cowen Caitlin Cronin - Canaccord Mason Carrico - Stephens Operator Thank you for standing by.
Read More
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative
Vericel Corporation (VCEL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.08 per share a year ago.
Read More
Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the …
Read More
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025.
Read More
Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22%
Read More
About Vericel Corporation (VCEL)
- IPO Date 1997-02-04
- Website https://vcel.com
- Industry Biotechnology
- CEO Dominick C. Colangelo
- Employees 357